Beaumont was the first hospital in Metro Detroit to treat patients in aclinical study evaluating the MitraClip system to repair the mitral valve without heart surgeryThe results of the clinical data that studied the MitraClip implant demonstrated safety, reduction of mitral valve regurgitation, rapid recovery, improvement in symptoms and reduction in hospitalizations for heart failure.
In October 2013, the FDA approved the use of the MitraClip to treat patients with degenerative mitral valve regurgitation. Beaumont was the first hospital in Michigan to implant the commercially approved MitraClip to help high-risk patients with degenerative mitral valve regurgitation. Surgery is typically not an option these patients because of the severity of their condition.
The MitraClip device is delivered to the heart through a small incision in the blood vessel in the leg. The heart continues to beat during the procedure and does not require a heart-lung bypass machine, which is common for open heart surgery. During the mitral valve repair procedure, a catheter (a thin, flexible plastic tube) is inserted through the patient's skin in the groin area and is guided through the femoral vein to the affected area of the heart. Then, a catheter that holds the MitraClip device goes in through the first catheter so that the MitraClip can be guided into place and attached to the leaflets of the mitral valve. Once the clip is properly placed and securely attached, it is deployed and the catheters are removed.
The MitralClip improves valve closure and reduces backflow of blood (regurgitation). The heart returns to pumping blood to the body more efficiently, relieving the patient's symptoms and improving their quality of life.